TW202233655A - 用於治療阿茲海默症之組合物及方法 - Google Patents

用於治療阿茲海默症之組合物及方法 Download PDF

Info

Publication number
TW202233655A
TW202233655A TW110139655A TW110139655A TW202233655A TW 202233655 A TW202233655 A TW 202233655A TW 110139655 A TW110139655 A TW 110139655A TW 110139655 A TW110139655 A TW 110139655A TW 202233655 A TW202233655 A TW 202233655A
Authority
TW
Taiwan
Prior art keywords
cdata
gly
lys
ser
ala
Prior art date
Application number
TW110139655A
Other languages
English (en)
Chinese (zh)
Inventor
菱谷彰徳
圭三 古屋
Original Assignee
美商碩拿生物科學有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商碩拿生物科學有限責任公司 filed Critical 美商碩拿生物科學有限責任公司
Publication of TW202233655A publication Critical patent/TW202233655A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110139655A 2020-10-26 2021-10-26 用於治療阿茲海默症之組合物及方法 TW202233655A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105,472 2020-10-26

Publications (1)

Publication Number Publication Date
TW202233655A true TW202233655A (zh) 2022-09-01

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110139655A TW202233655A (zh) 2020-10-26 2021-10-26 用於治療阿茲海默症之組合物及方法

Country Status (8)

Country Link
US (1) US20240025954A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232462A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548632A (cg-RX-API-DMAC7.html)
CN (1) CN117098771A (cg-RX-API-DMAC7.html)
AU (1) AU2021367952A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199433A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233655A (cg-RX-API-DMAC7.html)
WO (1) WO2022093736A1 (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
CN1440420A (zh) 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
WO2019161386A1 (en) 2018-02-19 2019-08-22 New York University Alpha-synuclein single domain antibodies
GB201902392D0 (en) * 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
JP2023520927A (ja) * 2020-04-10 2023-05-22 ソラ・バイオサイエンシズ・エルエルシー タンパク質凝集障害の処置のための組成物および方法
JP7894321B2 (ja) * 2020-04-28 2026-07-23 ソラ・バイオサイエンシズ・エルエルシー Tdp-43プロテイノパチーの処置のための組成物および方法

Also Published As

Publication number Publication date
AU2021367952A1 (en) 2023-06-08
CA3199433A1 (en) 2022-05-05
EP4232462A1 (en) 2023-08-30
CN117098771A (zh) 2023-11-21
JP2023548632A (ja) 2023-11-17
WO2022093736A1 (en) 2022-05-05
US20240025954A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
TW202206446A (zh) 用於治療tdp-43蛋白質病變之組合物及方法
US20230234997A1 (en) Compositions and Methods for the Treatment of Synucleinopathies
US20230226223A1 (en) Compositions and Methods for the Treatment of Protein Aggregation Disorders
US20240400626A1 (en) Compositions and methods for the treatment of p53-mediated cancers
JP2023521090A (ja) AAV遺伝子治療のためのCpGフリーITR
US20240115736A1 (en) Methods and materials for treating tdp-43 proteinopathies
US20240025954A1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease
RU2855933C1 (ru) Композиции и способы для лечения протеинопатий tdp-43
US20250042958A1 (en) Compositions and methods for the treatment of proteopathies
RU2851326C1 (ru) Композиции и способы лечения нарушений агрегации белков
CN117836420A (zh) 重组tert编码病毒基因组和运载体
HK40088984A (en) Compositions and methods for the treatment of tdp-43 proteinopathies
HK40092059A (en) Compositions and methods for the treatment of synucleinopathies
HK40087812A (en) Compositions and methods for the treatment of protein aggregation disorders
RU2828216C2 (ru) Модуляторы экспрессии гена открытой рамки считывания 72 хромосомы 9 и их применения
Al-Rafiah PLASTIN3 AS A THERAPEUTIC TARGET IN SPINAL MUSCULAR ATROPHY